ATE266420T1 - Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält - Google Patents
Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthältInfo
- Publication number
- ATE266420T1 ATE266420T1 AT99906366T AT99906366T ATE266420T1 AT E266420 T1 ATE266420 T1 AT E266420T1 AT 99906366 T AT99906366 T AT 99906366T AT 99906366 T AT99906366 T AT 99906366T AT E266420 T1 ATE266420 T1 AT E266420T1
- Authority
- AT
- Austria
- Prior art keywords
- cox
- inhibitors
- preparation containing
- combination preparation
- selective nmda
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940111134 coxibs Drugs 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9804886.1A GB9804886D0 (en) | 1998-03-06 | 1998-03-06 | Therapeutic combination |
| PCT/GB1999/000581 WO1999044640A1 (en) | 1998-03-06 | 1999-02-26 | Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE266420T1 true ATE266420T1 (de) | 2004-05-15 |
Family
ID=10828173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99906366T ATE266420T1 (de) | 1998-03-06 | 1999-02-26 | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1058559B1 (de) |
| JP (1) | JP2002505306A (de) |
| AT (1) | ATE266420T1 (de) |
| AU (1) | AU753079B2 (de) |
| CA (1) | CA2321687C (de) |
| DE (1) | DE69917230T2 (de) |
| ES (1) | ES2220047T3 (de) |
| GB (1) | GB9804886D0 (de) |
| WO (1) | WO1999044640A1 (de) |
| ZA (1) | ZA991744B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191512B (de) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| EP1186303A3 (de) * | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden |
| IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| EP1674087A1 (de) * | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten |
| ZA200108038B (en) * | 2000-10-02 | 2003-04-01 | Pfizer Prod Inc | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. |
| EP1399160A4 (de) * | 2001-06-12 | 2004-08-25 | Merck & Co Inc | Nr2b-rezeptor-antagonisten zur behandlung oder prävention von migräne |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| BRPI0415643A (pt) * | 2003-10-21 | 2006-12-12 | Arakis Ltd | uso de ifenprodil no tratamento de dor |
| JP2007529492A (ja) * | 2004-03-17 | 2007-10-25 | ソセイ・アール・アンド・ディー・リミテッド | β−アミノアルコール類を用いる炎症性障害及び疼痛の治療 |
| DK3664800T3 (da) * | 2017-08-09 | 2024-07-22 | Dechra Veterinary Products Llc | Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf |
| EP4041245A4 (de) * | 2019-11-01 | 2023-12-13 | Piedmont Animal Health Inc. | Therapeutische formulierungen und verwendungen davon |
| CN115515581A (zh) | 2020-01-10 | 2022-12-23 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗疼痛 |
| EP4087554A4 (de) | 2020-01-10 | 2024-01-17 | Pacira Pharmaceuticals, Inc. | Behandlung von schmerzen durch subarachnoidale verabreichung von liposomalen anästhetischen zusammensetzungen mit verzögerter freisetzung |
| US11918688B2 (en) | 2021-01-11 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of hip pain with sustained-release liposomal anesthetic compositions |
| CN117320696A (zh) | 2021-03-19 | 2023-12-29 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗儿科患者的疼痛 |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
| US12226610B2 (en) | 2022-11-03 | 2025-02-18 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions |
| WO2024217539A1 (zh) * | 2023-04-20 | 2024-10-24 | 纽欧申医药(上海)有限公司 | 含氮杂环类化合物及其制备方法和应用 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
| US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| DE69529690T2 (de) * | 1994-12-21 | 2003-11-13 | Merck Frosst Canada & Co., Halifax | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren |
-
1998
- 1998-03-06 GB GBGB9804886.1A patent/GB9804886D0/en not_active Ceased
-
1999
- 1999-02-26 WO PCT/GB1999/000581 patent/WO1999044640A1/en active IP Right Grant
- 1999-02-26 ES ES99906366T patent/ES2220047T3/es not_active Expired - Lifetime
- 1999-02-26 AT AT99906366T patent/ATE266420T1/de not_active IP Right Cessation
- 1999-02-26 JP JP2000534241A patent/JP2002505306A/ja active Pending
- 1999-02-26 EP EP99906366A patent/EP1058559B1/de not_active Expired - Lifetime
- 1999-02-26 DE DE69917230T patent/DE69917230T2/de not_active Expired - Lifetime
- 1999-02-26 CA CA002321687A patent/CA2321687C/en not_active Expired - Lifetime
- 1999-02-26 AU AU26329/99A patent/AU753079B2/en not_active Expired
- 1999-03-04 ZA ZA9901744A patent/ZA991744B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002505306A (ja) | 2002-02-19 |
| DE69917230T2 (de) | 2005-05-25 |
| ZA991744B (en) | 1999-09-13 |
| EP1058559A1 (de) | 2000-12-13 |
| DE69917230D1 (de) | 2004-06-17 |
| AU2632999A (en) | 1999-09-20 |
| CA2321687C (en) | 2008-04-22 |
| EP1058559B1 (de) | 2004-05-12 |
| AU753079B2 (en) | 2002-10-10 |
| CA2321687A1 (en) | 1999-09-10 |
| GB9804886D0 (en) | 1998-04-29 |
| ES2220047T3 (es) | 2004-12-01 |
| WO1999044640A1 (en) | 1999-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
| DE69728585D1 (de) | Mittel gegen Juckreiz | |
| IL155236A0 (en) | Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity | |
| NO996352D0 (no) | <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus | |
| WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| MXPA03007140A (es) | Derivados de carbolina. | |
| TR200000913T2 (tr) | Tıbbi maddeler | |
| NZ333723A (en) | A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor | |
| PL346876A1 (en) | Mglur5 antagonists for the treatment of pain and anxiety | |
| DE60009888D1 (de) | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| MY137620A (en) | Therapeutic treatment | |
| SE9802937D0 (sv) | Novel compounds | |
| AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
| BG105277A (en) | Prevention of migraine recurrence | |
| HUP0003836A2 (hu) | Lazofoxifent tartalmazó gyógyszerkészítmények | |
| ATE282417T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
| NO20001548L (no) | Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat | |
| CA2416879A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
| ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
| HK1033876A1 (en) | Use of nmda antagonists for treatment of irritablebowel syndrome. | |
| IL139144A0 (en) | Mycobacterial inhibitors | |
| AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
| DK1420789T3 (da) | Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling | |
| YU26001A (sh) | Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |